John Frank Carpenter

This inventor holds 31 USPTO granted patents and 9 published patent applications, plus 4 CIPO patents and 11 EPO patents, primarily in Vaccine Formulations. Top assignees: University of Colorado, University of Connecticut, Barofold, Inc.. Active years: 1999-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Frank Carpenter. Retrieved from https://idiyas.com/inventor/john-frank-carpenter

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 31 (Patent Applications = 9)

% Patents Active = 67.7

CIPO Patents = 4

EPO Patents = 11 (Patent Applications = 5)

Average Co-Inventor Count = 4.3

ph-index = 11

Forward Citations = 404(Granted Patents)

Location History:

Denver, CO (US) (2014)
Littleton, CO (US) (1999 - 2022)

Company Filing History:

13 out of 1,448

University of Colorado

patents

7 out of 783

University of Connecticut

Baxter International Inc.

University Technology Corporation

Becton Dickinson and Company Limited

patents

10. 1 out of 2

Endo Pharmaceuticals Colorado, Inc.

Xeris Pharmaceuticals, Inc.

patents

13. 1 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2025

Loading Chart...

Areas of Expertise:

Vaccine Compositions

Protein Formulations

Immunogenicity Reduction

Hypoglycemia Treatment

Albumin-Free Factor VIII

High Pressure Refolding

Adjuvant-Bound Vaccines

Sustained Drug Delivery

Supercritical Fluid Nebulization

Temperature Sensitive Gels

Protein Aggregation Evaluation

Pulmonary Administration

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12447127 - Thermostable vaccine compositions and methods of preparing the same (2025-10-21),

2. 12097291 - Thermostable vaccine compositions and methods of preparing same (2024-09-24),

3. 11491111 - Thermostable vaccine compositions and methods of preparing same (2022-11-08),

4. 9687527 - Stable glucagon formulations for the treatment of hypoglycemia (2017-06-27),

5. 9669076 - Albumin-free factor VIII formulations (2017-06-06),

6. 9352027 - Albumin-free factor VIII formulations (2016-05-31),

7. 8808710 - Method of preparing an immunologically-active adjuvant-bound dried vaccine composition (2014-08-19),

8. 8765665 - Albumin-free factor VIII formulations (2014-07-01),

9. 8710197 - High pressure refolding of protein aggregates and inclusion bodies (2014-04-29),

10. 8697848 - Method for reducing immunogenicity of therapeutic protein compositions (2014-04-15),

11. 8633034 - Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution (2014-01-21),

12. 8444991 - Method of preparing an immunologically-active adjuvant-bound dried vaccine composition (2013-05-21),

13. 8372800 - Albumin-free factor VIII formulations (2013-02-12),

14. 8372798 - High-concentration protein formulations and method of manufacture (2013-02-12),

15. 8329878 - Methods for protein refolding (2012-12-11),

Title: Unveiling the Legacy of John Frank Carpenter: Pioneering Innovator from Littleton

Introduction:

John Frank Carpenter, a brilliant inventor hailing from the picturesque town of Littleton, CO, has left an indelible mark on the world of biopharmaceuticals with his groundbreaking patents and innovative solutions.

Latest Patents:

Among his 29 patents, John Frank Carpenter's recent inventions include pioneering thermostable vaccine compositions and methods for preparing them. These compositions enhance the stability and efficacy of immunogenic agents, offering improved formulations for storage and delivery. Additionally, his stable glucagon formulations for treating hypoglycemia showcase his commitment to advancing patient care through cutting-edge solutions.

Career Highlights:

Having contributed significantly to the University of Colorado and the University of Connecticut, John Frank Carpenter's expertise and passion for scientific advancement have driven remarkable progress in the field of biopharmaceuticals. His relentless pursuit of excellence has led to the development of transformative technologies that have the potential to revolutionize healthcare.

Collaborations:

Throughout his illustrious career, John Frank Carpenter has collaborated with esteemed professionals such as Theodore W Randolph and Marc Besman. Together, they have synergized their expertise to drive innovation and push the boundaries of what is possible in the realm of biopharmaceutical research.

Conclusion:

In conclusion, John Frank Carpenter stands as a beacon of ingenuity and perseverance in the world of inventors. His exceptional contributions have not only enriched the field of biopharmaceuticals but also have the potential to positively impact countless lives. Littleton, CO, and the broader scientific community are privileged to have been touched by the brilliance of this visionary inventor.

Profile summary based on public USPTO records.